Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2008, for MB Software Corporation (Note: The input metadata lists "Sanara Medtech Inc.", but the filing text explicitly identifies the registrant as MB Software Corporation). The company operates primarily through its subsidiary, Wound Care Innovations, LLC, focusing on the development and marketing of advanced wound care products under the brand "CellerateRx(TM)". The company is classified as a smaller reporting company.
Key Financial Metrics
| Metric | Q1 2008 | Q1 2007 |
|---|---|---|
| Total Revenue | $63,270 | $83,941 |
| Cost of Sales | $148,236 | $26,999 |
| Gross Profit/(Loss) | $(84,966) | $56,942 |
| Net Loss | $(353,233) | $(173,253) |
| Loss Per Share (Basic/Diluted) | $(0.02) | $(0.01) |
| Cash and Cash Equivalents (End of Period) | $406,327 | $128,686 |
| Total Current Liabilities | $1,581,669 | N/A |
| Accumulated Deficit | $(13,352,615) | N/A |
Liquidity and Debt: The company reported a net cash inflow from financing activities of $1,211,970, driven by proceeds from unrelated party notes ($700,000) and stock sales ($300,000). However, the company has significant related-party debt and accrued interest. As of March 31, 2008, the company held $406,327 in cash against $1,581,669 in current liabilities.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by approximately 25% to $63,270 from $83,941 in the prior year quarter.
- Gross Margin Collapse: The company swung from a gross profit of $56,942 in Q1 2007 to a gross loss of $(84,966) in Q1 2008 due to a sharp increase in cost of sales ($148,236 vs. $26,999).
- Increased Net Loss: Net loss more than doubled to $(353,233) from $(173,253), driven by the gross loss and increased General and Administrative expenses ($271,602 vs. $202,102).
- Debt Restructuring: In January 2008, the company converted $1,495,664 of related-party debt into 490.196 shares of Series A Preferred stock.
Outlook, Risks, and Contingencies
Going Concern: The filing explicitly states that the company's ability to continue as a going concern is in substantial doubt. The company has continuously incurred losses and has a significant accumulated deficit. Future operations depend entirely on obtaining additional financing or equity capital.
Management Commentary: Management plans to raise capital through private placements, issuing stock for services, and obtaining loans from shareholders. They anticipate continuing to incur losses for at least the next twelve months.
Material Risks and Contingencies:
- Tax Delinquency: The company is delinquent on federal payroll taxes. As of March 31, 2008, unpaid taxes totaled approximately $203,000, with estimated penalties and interest of $123,000.
- Product Liability: The company faces inherent risks regarding product liability claims and adverse publicity related to its wound care products.
- Financing Risk: Failure to secure additional capital could force the company to curtail or cease operations.
Investor Verification Checklist
- Going Concern Status: Verify the company's ability to secure the additional capital required to meet obligations for the next 12 months.
- Tax Liability Resolution: Confirm the status of negotiations with the IRS regarding the $203,000 unpaid payroll taxes and $123,000 in penalties.
- Revenue Sustainability: Assess the viability of the "CellerateRx" product line given the 25% revenue decline and negative gross margin.
- Related Party Transactions: Review the terms and necessity of the significant related-party notes and the recent debt-to-equity conversion.
- Stock Issuance: Verify the issuance of 367,647 shares of common stock for $250,000, which was paid for but not issued as of the balance sheet date.